Do you want to read an article? Please log in or register.
Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial
Macular DiseasesRetinal Diseases
Related content
COMMENTED
Macular DiseasesRetinal Diseases
Macular Morphology and Visual Acuity in Year Five of the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology.
Jaffe GJ, Ying GS, Toth CA, Daniel E, Grunwald JE, Martin DF, Maguire MG; Comparison of Age-related Macular Degeneration Treatments Trials Research Group
doi: 10.1016/j.ophtha.
Macular Diseases
Characteristics of Eyes With Good Visual Acuity at 5 Years After Initiation of Treatment for Age-Related Macular Degeneration but Not Receiving Treatment From Years 3 to 5: Post Hoc Analysis of the CATT Randomized Clinical Trial
JAMA Ophthalmol.
Scoles D, Ying GS, Pan W, Hua P, Grunwald JE, Daniel E, Jaffe GJ, Toth CA, Martin DF, Maguire MG, Comparison of AMD Treatments Trials Research Group.
doi: 10.1001/jamaophthalmol.2019.5831.
COMMENTED
Macular Diseases
Morphological Reconstitution and Persistent Changes After Intravitreal Ocriplasmin for Vitreomacular Traction and Macular Hole
★ 1
Recommended by
Prof. Dr Daniel Barthelmes, Faculty Member
★ 2
Recommended and commented by
Dr habil. Gábor Márk Somfai, PhD, Faculty Member
J Ocul Pharmacol Ther.
Zandi S, Freiberg F, Vaclavik V, Pfister IB, Traine PG, Kaya C, Michels S, Garweg JG
doi: 10.1089/jop.2019.0051.
Macular Diseases
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results
Ophthalmology.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group., Writing Committee:., Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL 3rd
doi: 10.1016/j.ophtha.2020.01.029.
RECOMMENDED
LensesMacular Diseases
Follow up at 5 Years of Non-Fibrotic Scars in the Comparison of Age-related Macular Degeneration Treatments Trials (CATT)
Ophthalmology.
Daniel E, Ying GS, Kim BJ, Toth CA, Ferris F 3rd, Martin DF, Grunwald JE, Jaffe GJ, Dunaief JL, Pan W, Maguire MG; Comparison of Age-related macular degeneration Treatments Trials
doi: 10.1016/j.ophtha.2018.11.020.
Macular Diseases
Simultaneous Inhibition of Angiopoietin-2 and VEGF-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial
Ophthalmology.
Sahni J, Patel SS, Dugel PU, Khanani AM, Jhaveri CD, Wykoff CC, Hershberger VS, Pauly-Evers M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Osborne A, Weikert R, Fauser S
doi: 10.1016/j.ophtha.
COMMENTED
Macular Diseases
Canadian Treat and Extend Analysis Trial with Ranibizumab in Patients with Neovascular Age-related Macular Disease: 1-Year Results of the Randomized CANTREAT Study
Ophthalmology.
Kertes PJ, Galic IJ, Greve M, Williams RG, Rampakakis E, Scarino A, Sheidow T
doi: 10.1016/j.ophtha.
Macular DiseasesRetinal Diseases
Vitreomacular adhesion or vitreomacular traction may affect antivascular endothelium growth factor treatment for neovascular age-related macular degeneration
Br J Ophthalmol.
Xie P, Zheng X, Yu Y, Ye X, Hu Z, Yuan D, Liu Q
doi: 10.1136/bjophthalmol-
COMMENTED
Macular DiseasesSurgery and Intervention
Facedown Positioning Following Surgery for Large Full-Thickness Macular Hole: A Multicenter Randomized Clinical Trial
★ 2
Recommended and commented by
Prof. Dr Stephan Michels, Faculty Member
★ 3
Recommended by
Prof. Dr Ke Yao, Faculty Member
doi: 10.1001/jamaophthalmol.2020.0987.